A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

被引：0
|
作者：
Watts, Justin M. [1 ]
Swords, Ronan T. [2 ]
Cogle, Christopher R. [3 ]
Lin, Tara L. [4 ]
机构：
[1] Univ Miami, Leukemia Program, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Florida, Div Hematol Oncol, Dept Med, Gainesville, FL USA
[4] Univ Kansas Canc Ctr, Kansas City, KS USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4037.4037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4037
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Watts, Justin M.
    Swords, Ronan T.
    Cogle, Christopher R.
    Schiller, Gary J.
    Lin, Tara L.
    [J]. BLOOD, 2017, 130
  • [2] A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Uckun, Fatih M.
    Cogle, Christopher R.
    Lin, Tara L.
    Qazi, Sanjive
    Trieu, Vuong N.
    Schiller, Gary
    Watts, Justin M.
    [J]. CANCERS, 2020, 12 (01)
  • [3] A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Turner, Daniel
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Bosse, Raphael C.
    Chaplin, Dai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Norkin, Maxim
    Wingard, John R.
    Cogle, Christopher R.
    [J]. BLOOD, 2013, 122 (21)
  • [4] A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Norkin, Maxim
    Chaplin, David
    Balkissoon, Jai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Wingard, John R.
    [J]. BLOOD, 2012, 120 (21)
  • [5] Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Swaminathan, Mahesh
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Walinski, Wendy
    Wang, Eunice S.
    [J]. BLOOD, 2021, 138
  • [6] A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Cripe, Larry D.
    Michelson, Glenn C.
    Fox, Judith A.
    Leavitt, Richard D.
    Chen, Tianling
    Hawtin, Rachael
    Craig, Adam R.
    Ravandi, Farhad
    Maris, Michael B.
    Stuart, Robert K.
    Karp, Judith E.
    [J]. HAEMATOLOGICA, 2015, 100 (02) : 231 - 237
  • [7] Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes
    Cogle, Christopher R.
    Collins, Bradley
    Turner, Daniel
    Pettiford, Leslie C.
    Bosse, Raphael
    Hawkins, Kimberly E.
    Beachamp, Zackary
    Wise, Elizabeth
    Cline, Christina
    May, William S.
    Moreb, Jan S.
    Hsu, Jack
    Hiemenz, John
    Brown, Randall
    Norkin, Maxim
    Wingard, John R.
    Uckun, Fatih
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : E211 - E213
  • [8] Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study
    de Vos, S.
    Swinnen, L. J.
    Wang, D.
    Reid, E.
    Fowler, N.
    Cordero, J.
    Dunbar, M.
    Enschede, S. H.
    Nolan, C.
    Petrich, A. M.
    Ross, J. A.
    Salem, A. H.
    Verdugo, M.
    Agarwal, S.
    Zhou, L.
    Kozloff, M.
    Nastoupil, L. J.
    Flowers, C. R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (09) : 1932 - 1938
  • [9] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
  • [10] Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
    Cortes, Jorge
    Talpaz, Moshe
    Smith, Hedy P.
    Snyder, David S.
    Khoury, Jean
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard
    Mitchell, David
    Wise, Scott C.
    Rutkoski, Thomas J.
    Smith, Bryan D.
    Flynn, Daniel L.
    Kantarjian, Hagop M.
    Rosen, Oliver
    Van Etten, Richard A.
    [J]. HAEMATOLOGICA, 2017, 102 (03) : 519 - 528
12345